This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): LymphoCide, hLL2, AMG412, IMMU-103
Due to different partnerships, BioMedTracker maintains separate drug profiles for Epratuzumab, Epratuzumab-SLE, Epratuzumab Th-227, and Y-90 Epratuzumab.
Epratuzumab is a humanized monoclonal antibody that targets the B cell specific antigen CD22.
Immunomedics and Amgen
In December 2000, Immunomedics announced a partnership with Amgen to develop LymphoCide. Amgen will develop and market LymphoCide in North America and Australia. Amgen will be responsible for commercial manufacturing and will assume sponsorship of the U.S. INDs. Amgen will also receive rights to second-generation products including radiolabeled epratuzumab.
The agreement includes an $18 million up-front payment to Immunomedics and clinical milestone payments potentially totaling $65 million and royalties. The agreement provides for one-time sales milestone payments totaling $50 to $225 million if and when annual net sales reach $500 million to $1 billion.
In late 2003, both Amgen and Immunomedics announced that Amgen would not continue as a partner in the development of epratuzumab.
Immunomedics and UCB
In May 2006, Immunomedics and UCB announced a collaboration and license agreement for epratuzumab. The agreement grants...See full deal structure in Biomedtracker
Pink Sheet Amgen seeking developer for epratuzumab
Additional information available to subscribers only: